BioSpace News Archive

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced positive results from its Phase 2, open-label, multicenter study of mitapivat in adults with non-transfusion dependent α- or β-thalassemia.

Heartseed, a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, announced it has raised 4 Billion-yen at Series C round, bringing its total financial backing to 8.2 Billion yen since its foundation in 2015.

BeiGene, Ltd. announced long-term follow-up results from three pivotal trials in its hematology program at the 26th EHA 2021 Virtual Congress, including a pivotal Phase 2 trial of its anti-PD-1 antibody tislelizumab in relapsed or refractory classical Hodgkin’s lymphoma in an oral presentation, and two pivotal Phase 2 trials of its BTK inhibitor BRUKINSA® in R/R mantle cell lymphoma and in R/R chronic lymphocytic leukemia or small lymphocytic lymphoma in poster presentations.

Bristol Myers Squibb and Acceleron Pharma Inc. announced the first data from the Phase 2 BEYOND study evaluating Reblozyl®, a first-in-class erythroid maturation agent, plus best supportive care in adult patients with non-transfusion dependent beta thalassemia, were presented at the European Hematology Association 2021 Virtual Congress as part of its Presidential Symposium.

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced new data on 22 patients, with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment.

Cadwell Industries, Inc., a global leader in neurodiagnostic and neuromonitoring solutions, announces a partnership with EnsoData, a healthcare artificial intelligence company dedicated to improving the lives of medical professionals and their patients.

Mustang Bio, Inc. announced updated interim data from the ongoing Phase 1/2 clinical trial investigating the safety and efficacy of MB-106 CD20-targeted, autologous CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1x1 investor meetings at the JMP Securities Life Sciences Conference taking place from June 16-17, 2021.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of innovative Anti-Cancer Therapy technologies intended to safely and effectively destroy various cancers, bacteria and viruses, while preserving patient Quality Of Life announced the launch of the seventh US-based Clinical Study Site ; specifically, the University of Chicago Medicine.

Avacta Group plc is pleased to announce that it has received notice of registration of its AffiDX® SARS-CoV-2 antigen lateral flow test in the EU.